5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where
components of blood such as red cells, platelets and white cells are made. In bone marrow
failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic
syndrome, this decreased bone marrow function is believed to result from abnormalities that
prevent the normal maturation process by which bone marrow cells develop into red blood
cells, white blood cells and platelets. In myelodysplastic syndrome, these abnormal bone
marrow cells occupy space in the bone marrow and prevent the function of remaining normal
bone marrow cells.
One approach to treating the abnormal growth of immature cells is to give chemotherapy which
damages DNA within these cells and causes their death. Unfortunately, such therapy has
side-effects, since even normal cells can be affected by the treatment. Both 5-azacitidine
(5AZA) and decitabine (DEC) are FDA-approved to treat MDS. In this study, 5AZA and DEC will
be administered using an alternating low doses schedule in an attempt to overcome the known
mechanisms of resistance to the administration of 5AZA or DEC as single agents caused by
automatic adaptive shifts in DNA metabolism.
Phase:
Early Phase 1
Details
Lead Sponsor:
Benjamin Tomlinson Case Comprehensive Cancer Center